SRR10900014
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.400
- OXIDATIVE_PHOSPHORYLATION+0.400
- E2F_TARGETS+0.300
- G2M_CHECKPOINT+0.300
- SPERMATOGENESIS+0.300
- ADIPOGENESIS+0.200
- MYC_TARGETS_V2+0.200
- PANCREAS_BETA_CELLS+0.200
- PI3K_AKT_MTOR_SIGNALING+0.200
- PROTEIN_SECRETION+0.200
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.500
- ANGIOGENESIS-0.400
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.400
- HEDGEHOG_SIGNALING-0.400
- INTERFERON_GAMMA_RESPONSE-0.400
- TGF_BETA_SIGNALING-0.400
- TNFA_SIGNALING_VIA_NFKB-0.400
- COAGULATION-0.300
- IL2_STAT5_SIGNALING-0.300
- IL6_JAK_STAT3_SIGNALING-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-66-2754-01A-01R-0980-07 | — | cohortA3 | 0.900 |
| 2 | TCGA-QK-A6VB-01A-12R-A34R-07 | — | — | 0.895 |
| 3 | fd49c74b-2a85-46cd-aaa0-dbd2f1284947 | — | — | 0.891 |
| 4 | AUR-AFR3-TTM1-A-1-1-R-A743-41 | — | C | 0.885 |
| 5 | TCGA-QK-A8ZA-01A-11R-A39I-07 | — | — | 0.881 |
| 6 | SRR4195684 | — | — | 0.880 |
| 7 | SRR26320088 | — | — | 0.879 |
| 8 | TCGA-A8-A06Q-01A-11R-A034-07 | — | C | 0.878 |
| 9 | SRR2932846 | — | — | 0.877 |
| 10 | TCGA-33-4582-01A-01R-1443-07 | — | cohortSQ2 | 0.877 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.400 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.400 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.300 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.300 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.300 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.200 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.200 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.200 | Cobimetinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.200 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.200 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.200 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.200 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.100 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.100 | Inavolisib | — uncovered |
| PEROXISOME | 0.100 | Idelalisib | — uncovered |